Asco 2023 – Elevation follows in Astellas’s slipstream
There is reason for the enthusiasm behind Elevation’s anti-Claudin18.2 ADC, but no such good news for Zai Lab’s zolbetuximab challenger.
Another strike for biotech: China
Use of an auditor that cannot be inspected by the US regulator takes centre stage as Chinese biotech stocks fall.
Global pharma stocks struggle in the third quarter
A strong performance from a handful of large drug developers could not rescue the sector from a weak three months on the stock market.
Trillium gets a buyout while it's down
The latest deal over a CD47 asset has got investors wondering who could be next.